Edwards Lifesciences Corp (EW)vsenVVeno Medical Corp (NVNO)
EW
Edwards Lifesciences Corp
$92.21
+0.96%
HEALTHCARE · Cap: $54.60B
NVNO
enVVeno Medical Corp
$11.31
+2.82%
HEALTHCARE · Cap: $7.42M
Smart Verdict
WallStSmart Research — data-driven comparison
EW leads profitability with a 17.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 56/100 (C).
EW
Buy56
out of 100
Grade: C
NVNO
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$251.46
Current Price
$92.21
$159.25 discount
Intrinsic value data unavailable for NVNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
16.7% revenue growth
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : NVNO
The strongest argument for NVNO centers on Price/Book, Debt/Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.3x leaves little room for execution misses.
Bear Case : NVNO
The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
EW profiles as a growth stock while NVNO is a value play — different risk/reward profiles.
NVNO carries more volatility with a beta of 1.09 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
NVNO generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
EW scores higher overall (56/100 vs 27/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →enVVeno Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?